



18th Workshop

EURORDIS Round Table of Companies (ERTC)

Corporate Responsibility in Improving Access to Orphan Medicinal Products

Wednesday 27 February, 2013 (9:00 to 16:30)

Brussels, Belgium

Hotel Le Plaza Brussels, Boulevard Adolphe Max 118 -126

AGENDA

Chairperson: Mr. Yann Le Cam (EURORDIS, CEO)	
9:00 – 9:30	Welcome address: Yann Le Cam
9:30 – 11:20	<i>Corporate Responsibility & National Measures</i>
9:30-9:50	Corporate Responsibility: Dr. Thomas Heynisch (European Commission, DG Enterprise)
9:50-10:20	Panel discussion involving Dr. Adam Heathfield (Pfizer) and Dr. Paolo D. Siviero (Italian Medicines Agency (AIFA))
10:20-10:50	National Measures to improve access to orphan medicinal products in the context of national plans: Ms. Wills Hughes-Wilson (SOBI/EBE-EuropaBio)
10:50 – 11:20	COFFEE BREAK
11:20 – 13:10	<i>Differential Pricing</i>
11:20 - 11:45	Differential pricing: Mr. Johan Van Calster (former Head of the Belgian Medicines Agency and special advisor to Fipra for the Differential Pricing project)
11:45 – 12:10	Panel discussion involving Mr. Richard Bergström (tbc.), Ms. Flaminia Macchia (EURORDIS) and Mr. Francis Arickx (RIZIV / INAMI)
12:10 – 13:10	Parallel breakout sessions <ul style="list-style-type: none"> • National Measures: What are the measures included in the National Plans for Rare Diseases that should be promoted as priorities in order to improve access to OMPs? • Differential Pricing: Is the approach proposed in the Non Paper on Differential Pricing sufficient for improving access to OMPs and under which conditions? • Mechanism of Coordinated Access to OMPs: What are the key success factors necessary for making the Common Assessment of the Value of OMP based on the European Transparent Value Framework work?
13:10 – 14:30	LUNCH

Chairpersons: Professor Kerstin Westermark (MPA, Sweden) and Mr. Patrick Deboyser (European Commission, DG Health & Consumers)

14:40 – 16:30	<i>Feedback from breakout sessions - How to address the challenges of access to orphan medicinal products in the countries most affected by the crisis</i>
14:40 – 15:10	Feedback from each of the 3 breakout sessions 10' each
15:10 – 15:35	How to address the challenges of access in countries most affected by the crisis: Mr. Richard Bergström (EFPIA)
15:35 – 16:15	Panel discussion involving Professor Bruno Sepodes (Chairperson, COMP, EMA); Mr. Dimitrios Synodinos (BoD EURORDIS/Greek Alliance for Rare Diseases); Drs. Mohit Jain (BioMarin Europe) and Kevin Loth (Celgene Europe)
16h15 – 16:30	Conclusions
16:30	Meeting ends